ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.537,14
-0,17%
S&P 500
5.321,41
0,25%
US Dollar vs BRL
5,1158
0,22%
Bitcoin
69.486,00
-2,75%
Brent Oil
82,755
-0,93%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Protara Therapeutics Inc (TARA)

  7. Protara Therapeutics Inc (TARA) Notícias

TARA

Protara Therapeutics (TARA)

Protara Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:TARA
DataHoraFonteTítuloCódigoCompanhia
21/05/202409:00GlobeNewswire Inc.Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation SummitNASDAQ:TARAProtara Therapeutics Inc
17/05/202420:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
10/05/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TARAProtara Therapeutics Inc
09/05/202417:31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TARAProtara Therapeutics Inc
02/05/202409:00GlobeNewswire Inc.Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:TARAProtara Therapeutics Inc
05/04/202409:04GlobeNewswire Inc.Protara Therapeutics Announces Oversubscribed $45 Million Private Placement FinancingNASDAQ:TARAProtara Therapeutics Inc
05/04/202409:02GlobeNewswire Inc.Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral NutritionNASDAQ:TARAProtara Therapeutics Inc
05/04/202409:00GlobeNewswire Inc.Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBCNASDAQ:TARAProtara Therapeutics Inc
13/03/202409:00GlobeNewswire Inc.Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:TARAProtara Therapeutics Inc
28/02/202410:00GlobeNewswire Inc.Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care ConferenceNASDAQ:TARAProtara Therapeutics Inc
30/11/202310:30GlobeNewswire Inc.Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic OncologyNASDAQ:TARAProtara Therapeutics Inc
03/11/202309:31Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:TARAProtara Therapeutics Inc
03/11/202309:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TARAProtara Therapeutics Inc
03/11/202309:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TARAProtara Therapeutics Inc
03/11/202309:00GlobeNewswire Inc.Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business UpdateNASDAQ:TARAProtara Therapeutics Inc
23/10/202309:00GlobeNewswire Inc.Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic MalformationsNASDAQ:TARAProtara Therapeutics Inc
20/09/202309:30GlobeNewswire Inc.Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in SituNASDAQ:TARAProtara Therapeutics Inc
05/09/202308:30GlobeNewswire Inc.Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:TARAProtara Therapeutics Inc
03/08/202309:00GlobeNewswire Inc.Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business UpdateNASDAQ:TARAProtara Therapeutics Inc
27/06/202320:26Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TARAProtara Therapeutics Inc
08/06/202317:07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TARAProtara Therapeutics Inc
15/05/202309:00GlobeNewswire Inc.Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in SituNASDAQ:TARAProtara Therapeutics Inc
04/05/202309:11Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:TARAProtara Therapeutics Inc
04/05/202309:00GlobeNewswire Inc.Protara Therapeutics Announces First Quarter 2023 Financial Results and Business UpdateNASDAQ:TARAProtara Therapeutics Inc
02/05/202309:00GlobeNewswire Inc.Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic MalformationsNASDAQ:TARAProtara Therapeutics Inc
28/04/202309:00GlobeNewswire Inc.Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical DevelopmentNASDAQ:TARAProtara Therapeutics Inc
26/04/202317:12Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:TARAProtara Therapeutics Inc
26/04/202317:10Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:TARAProtara Therapeutics Inc
26/04/202317:06Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:TARAProtara Therapeutics Inc
08/03/202318:11Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:TARAProtara Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:TARA

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PDGR3
PDG REALT ON
BOV
HAGA3
HAGA ON
BOV
PRIO3
PETRORIO ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
COGN3
COGNA ON
BOV
SGPS3
SPRINGS ON
BOV
INBR32
Inter &
BOV
BHIA3
Grupo Casas Bahia ON
BOV
GFSA3
GAFISA ON
BOV
IFCM3
Infracommerce Caxaas ON
BOV
HOOT4
HOTEIS OTHON PN
BOV
HBOR3
HELBOR ON
BOV
JHSF3
JHSF PART ON
BOV
LUPA3
LUPATECH ON
BOV
IRBR3
IRB BRASIL ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados